160 related articles for article (PubMed ID: 17367342)
1. Understanding the mechanisms and limitations of immune control of HIV.
Davenport MP; Ribeiro RM; Zhang L; Wilson DP; Perelson AS
Immunol Rev; 2007 Apr; 216():164-75. PubMed ID: 17367342
[TBL] [Abstract][Full Text] [Related]
2. The dynamics of the cellular immune response to HIV infection: implications for vaccination.
McMichael AJ; Callan M; Appay V; Hanke T; Ogg G; Rowland-Jones S
Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1007-11. PubMed ID: 11186301
[TBL] [Abstract][Full Text] [Related]
3. Anti-HIV adaptive immunity: determinants for viral persistence.
Yamamoto H; Matano T
Rev Med Virol; 2008; 18(5):293-303. PubMed ID: 18416450
[TBL] [Abstract][Full Text] [Related]
4. New paradigms for generating effective CD8+ T cell responses against HIV-1/AIDS.
Ahlers JD; Belyakov IM
Discov Med; 2010 Jun; 9(49):528-37. PubMed ID: 20587342
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-induced T cells control reversion of AIDS virus immune escape mutants.
Fernandez CS; Smith MZ; Batten CJ; De Rose R; Reece JC; Rollman E; Venturi V; Davenport MP; Kent SJ
J Virol; 2007 Apr; 81(8):4137-44. PubMed ID: 17251297
[TBL] [Abstract][Full Text] [Related]
6. Cellular immune responses to HIV.
McMichael AJ; Rowland-Jones SL
Nature; 2001 Apr; 410(6831):980-7. PubMed ID: 11309628
[TBL] [Abstract][Full Text] [Related]
7. HIV/AIDS vaccines: 2007.
Robinson HL
Clin Pharmacol Ther; 2007 Dec; 82(6):686-93. PubMed ID: 17971817
[TBL] [Abstract][Full Text] [Related]
8. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
[TBL] [Abstract][Full Text] [Related]
9. Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity.
Su J; Willert C; Comanita L; Peters A; Gilbert PA; Strathdee C; O'Connell PJ; McFadden GD; Dekaban GA
Virology; 2008 May; 375(1):48-58. PubMed ID: 18291435
[TBL] [Abstract][Full Text] [Related]
10. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
Li W; Li S; Hu Y; Tang B; Cui L; He W
Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
[TBL] [Abstract][Full Text] [Related]
12. Viral and host factors in the pathogenesis of HIV infection.
Derdeyn CA; Silvestri G
Curr Opin Immunol; 2005 Aug; 17(4):366-73. PubMed ID: 15955686
[TBL] [Abstract][Full Text] [Related]
13. Hitting HIV where it hurts: an alternative approach to HIV vaccine design.
Altfeld M; Allen TM
Trends Immunol; 2006 Nov; 27(11):504-10. PubMed ID: 16997629
[TBL] [Abstract][Full Text] [Related]
14. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
[TBL] [Abstract][Full Text] [Related]
15. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
16. The role of the SIV model in AIDS vaccine research.
Friedrich TC; Watkins DI
IAVI Rep; 2005; 9(2):1, 6-8. PubMed ID: 16156073
[No Abstract] [Full Text] [Related]
17. Rates of HIV immune escape and reversion: implications for vaccination.
Davenport MP; Loh L; Petravic J; Kent SJ
Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
[TBL] [Abstract][Full Text] [Related]
18. Modelling the influence of activation-induced apoptosis of CD4+ and CD8+ T-cells on the immune system response of a HIV-infected patient.
Stan GB; Belmudes F; Fonteneau R; Zeggwagh F; Lefebvre MA; Michelet C; Ernst D
IET Syst Biol; 2008 Mar; 2(2):94-102. PubMed ID: 18397120
[TBL] [Abstract][Full Text] [Related]
19. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
20. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location.
Masopust D
J Intern Med; 2009 Jan; 265(1):125-37. PubMed ID: 19093965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
